PRW Pro Pharmaceuticals

[Tooty]

Just got a little taste @.31

Lotta news and volume is getting up there.


Pro-Pharmaceuticals' Begins Process of New Drug Application Submission with the FDA for Co-administration of DAVANAT(R) with 5-FU in Cancer Patients
Wednesday February 7, 7:00 am ET

NEWTON, Mass.--(BUSINESS WIRE)--Pro-Pharmaceuticals, Inc. (Amex: PRW - News), a developer of novel carbohydrate compounds, today announced it has begun the process of submitting a New Drug Application (NDA) with the U.S. Food & Drug Administration (FDA) for co-administration of DAVANAT® with 5-Fluorouracil (5-FU) for treatment in cancer patients.

"Our goal is to get our lead compound, DAVANAT® to market," said David Platt, Ph.D., President & Chief Executive Officer, Pro-Pharmaceuticals, Inc. "Based on recent data analysis from our Phase l and Phase ll clinical trials, we believe DAVANAT® has the potential to improve the pharmacokinetic profile of 5-FU, as well as other FDA-approved anti-cancer drugs, with out increasing toxicity markers as would be expected with increased 5-FU exposure. In addition, we continue discussions with pharmaceutical companies who are evaluating our technology. Our goal is to facilitate collaborations that will enable us to get our compounds to market quickly in multiple indications and modalities."

Analysis of the pharmacokinetic data of the Phase l clinical trial indicates that 5-FU, in combination with DAVANAT®, remained longer in the bloodstream (up to 10 times), without increasing 5-FU's toxicity in these fragile patients. Increased exposure to 5-FU may explain why 54% (14 of 26) of the end-stage cancer patients, who had measurable disease, were stabilized from 2 to 13 months and 70% (7 of 10) were stabilized at the highest DAVANAT® dose level. In the Phase ll clinical trial for end stage cancer patients, patients had no increase in toxicity with increased exposure to 5-FU in the presence of DAVANAT®.

The Company is actively recruiting and dosing patients in two international Phase ll trials both designed as first-line therapies in colorectal and biliary cancers, administering DAVANAT® in combination with 5-FU. In the colorectal trial, AVASTIN® and Leucovorin are also administered. Additional information on these two trials can be found at www.clinicaltrials.gov.

About DAVANAT®

DAVANAT®, the Company's lead drug candidate, is a carbohydrate (polysaccharide) polymer composed of mannose and galactose. The Company believes DAVANAT®'s mechanism of action is based upon binding to lectins on the cell surface. Lectins are carbohydrate-binding proteins found in increased amounts on cell surfaces. DAVANAT®, when injected into humans, recognizes and attaches to lectins. It is theorized that DAVANAT® targets specific lectin receptors (Galectins) that are over-expressed on cancer cells. Current research indicates that Galectins affect cell development and play important roles in cancer, including tumor cell survival, angiogenesis and tumor metastasis. This form of targeted delivery may allow for higher doses of chemotherapy administration with no increase in toxicity.

Pro-Pharmaceuticals, Inc. - Advancing Drugs Through Glycoscience®

Pro-Pharmaceuticals is a development stage pharmaceutical company engaged in the discovery, development and commercialization of carbohydrate-based therapeutic compounds for advanced treatment of cancer, liver, microbial, cardiovascular and inflammatory diseases. Initially, the product pipeline is principally focused on increasing the efficacy and decreasing the toxicity of approved chemotherapy drugs. The Company has been conducting clinical and pre-clinical studies with its lead compound, DAVANAT®, in combination with 5-FU, leucovorin, irinotecan, doxorubicin, oxaliplatin, paclitaxel, cisplatin, and bevacizumab (Avastin®). Results show that DAVANAT® exhibits a broad spectrum of activity with tested drugs. The Company is developing other carbohydrate-based therapeutic compounds that are currently in the pre-clinical stage of development. Founded in 2000, the Company is headquartered in Newton, Mass. Additional information is available at www.pro-pharmaceuticals.com.

[rfi]

Nice, up 35% so far today. I picked up some at .31.

[Tooty]

hit .45 today

[metalheadrr3]

Eh, timed it wrong. In at .42 thinking I could get a few quick pennies out of it today but it quickly fell and hit my limit of .40. Oh well, we'll see what's shakin monday ... this things seems to take off in early trading so I might look at gettin in closer to the bell.

[rfi]

Up to a high of .59 today. over 40% move nice if you are still in this one.

[metalheadrr3]

.... begins kicking myself ....

Props to you all on this one. Sad to say I missed out.

[Tooty]

Way passed 100% profit.

[rfi]

Up another 50% today. I have been in and out of this stock a few times over the last week. Made money each time. Any thoughts on if this will keep climbing? Reached a high of $1.08 today so far!

[metalheadrr3]

This is getting a little crazy. As long as it has momentum enjoy the ride ... I really want to short this thing though ... once it does turn negative =)

[gotcramer?]

Got in at .44 and made some cash. Then again at .70 and made some dough. I need to start riding some of these out longer with some good stops. Who knew?

Anybody in WTVI? I heard to stay away from that one but wow! I'd worry about liquidity.